An observational study in Crohn Disease (CD), Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD), sponsored by Imelda GI Clinical Research Center. Not yet recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Imelda GI Clinical Research Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies in Crohn Disease with a site in Belgium — 41 open to participants now, 56 under way, 29 of them phase 3. Crohn Disease · Belgium.
Among the 194 studies in Crohn Disease with a site in Belgium, this one is the 15th largest by planned enrollment of the 19 observational ones that give a count, is one of 13 that started in 2025, is one of 19 observational ones, reaches primary completion later than 12 of the 55 other live ones, and was the 185th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →41 of the 194 studies in Crohn Disease with a site in Belgium are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Belgium, United States, Argentina and 27 more countries
Ages 18+
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Imelda GI Clinical Research Center · Sites in Belgium
Ages 16+
Janssen Research & Development, LLC · Sites in Belgium, United States, Austria and 14 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 58 · Phase 3 94 · Phase 4 9
First in 2001; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 184 across 646 observational studies indexed under Crohn Disease.
Median enrollment 211 across the 175 interventional studies, 257 across the 19 observational. Of the 135 that completed or were terminated, 83 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 194 have an industry lead sponsor. The 10 most frequent:
Imelda GI Clinical Research Center is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Imelda GI Clinical Research Center has 3 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Crohn Disease with a site in Belgium that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
Add all 15 to your calendar (.ics) → With an account.
Among the 194 studies in Crohn Disease with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To develop digital biomarkers associated with disease activity of inflammatory bowel disease
The trial aims to develop digital biomarkers based on a large dataset of imput data. These data come from diffent sources including wearable data, grocery shopping data, patient reported outcome data, laboratory data and technical exam data. A model will be build that predict disease activity in IBD.
This is an open label observational trial with partially blinded data collection (wearable and shopping data blinded for the patient and treating HCP). Patients in the study will not be randomized. Patients will be recruited via planned outpatient visits and day clinic admissions. Patients will be allocated to one of the three target patient groups at the investigator's discretion.
From the moment 60 patients are included, no additional patients can be recruited in group 1 or 3 prior to completion of group 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Patients with IBD in longstanding remission (\>2 years) (maximum of 20 patients) 2. Patients with IBD recent event (diagnosis or flare of IBD) (\<1year) (minimum 20 patients) 3. Additional patients with IBD in standard follow up.
Device: monitoring of wearable data, shopping data, biomarkers and patient reported outcomes
1. All participants will receive a wearable device type Corsano Health Cardio watch 287-2 which is provided by the sponsor via Inovigate. Participants will be encouraged to wear the device 24h per day and need to wear the wearable device at least 12 hours per day, preferential during daytime. 2. All participants will receive a loyalty card (Xtra card Colruyt group) which is provided by the sponsor via Inovigate for food data capturing. The patient is requested to execute all grocery shopping at one of the Colruyt Group stores. He/she will always need to offer the loyalty card to the cashier prior to payment. The purchase receipt will then be automatically sent to the central food data repository at the sponsor set up for this study. Non-food or non-food related data will neither be captured nor stored during the trial. 3. biomarkers in blood and feaces will be monitored according to standard of care 4. patient reported outcomes will be monitored according to standard of care
Proportion of patients in which a flare can be detected based on passive monitoring data.
Time frame: 1 year
Proportion of patients in which a biomarker flare can be detected based on passive monitoring data
Time frame: 1 year
Proportion of patients in which an objective disease flare (combination of flare and biomarker flare) can be detected based on passive monitoring
Time frame: 1 year
Proportion of patients in which a flare can be detected based on food purchase data
Time frame: 1 year
Proportion of patients in which a biomarker flare can be detected based on food purchase data
Time frame: 1 year
Proportion of patients in which an objective disease flare (combination of flare and biomarker flare) can be detected based on food purchase data
Time frame: 1 year
- Interval between onset of a flare and detection based on passive monitoring data
exploratory outcome
Time frame: 1 year
- Subgroup analysis based on the food frequency questionnaire
Exploratory outcome
Time frame: 1 year
- Patient satisfaction based on patient experience questionnaire
Exploratory outcome
Time frame: 1 year
- Proportion of patients in which (different levels of) disability can be detected based on passive monitoring data
.exploratory outcome
Time frame: 1 year
- Proportion of patients in which a change of IBD medication can be detected based on passive monitoring data
Exploratory outcome
Time frame: 1 year
Plan to share: No
Start is estimated for Sep 2025; primary completion for Sep 2026, 12 months later.
Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's planned 12 months is below that.
Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Imelda GI Clinical Research Center